Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could moving HIV care out of hospitals boost satisfaction and cut carbon?

NCT ID NCT07792070

Disease control Sponsor: Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This pilot study tests whether people with HIV who receive routine care at a community center, instead of a hospital, feel more satisfied with their care. Researchers will compare satisfaction between two groups: one getting care at the community facility and one continuing usual hospital follow-up. The study also looks at whether community-based care reduces the carbon footprint. Participants will have medical visits, blood tests, and collect their antiretroviral medication every two months over 24 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Decentralization of HIV medical care, including follow-up visits, antiretroviral collection, and analytical tests at a community facility (BCN Checkpoint) instead of a hospital
What this could lead to
If this works, community-based HIV care could become a standard option, improving patient satisfaction and reducing the environmental impact of hospital visits.
What could go wrong
This is a small pilot study with 54 participants, so results may not apply broadly. Decentralized care might not suit everyone, and satisfaction could vary.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

54 people

The number who actually took part.

Started

Nov 2024

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Stable ARV treatment for ≥6 months with oral medications including: * Biktarvy (bictegravir/emtricitabina/tenofovir alafenamida) * Dovato (dolutegravir/lamivudina) * Juluca (dolutegravir/rilpivirina) * dolutegravir + emtricitabina/tenofovir * Symtuza (darunavir/cobicistat/emtricitabina/tenofovir alafenamida) * Undetectable HIV viral load for ≥6 months. * Good treatment adherence according to the HIV and pharmacy teams. * Good adherence to medical appointments * Using a mobile app and acceptance of the established process. * Signed Informed Consent. Exclusion Criteria: * Acute disease or decompensated chronic diseases in the last 6 months. * Any other condition that advises against out-of-hospital follow-up. * Participants who are already using the locker system to pick up their medication. * Pregnant Women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Health care delivery are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Health care delivery HIV HIV antiretroviral therapy (ART) adherence

Contacts and locations

Locations

  • Hospital Universitario Germans Trias i Pujol

    Badalona, Barcelona, 08916, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.